Anavex Compound to be Tested in Biogen Neurological Protection Model
28 September 2016 - 9:00PM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer, today announced that it has
signed a material transfer agreement with Biogen (Cambridge, MA)
under which Biogen will test Anavex’s lead drug candidate, ANAVEX
2-73 in an oligodendrocyte precursor cell (OPC) differentiation
assay. A satisfactory result from the OPC assay study may lead to
an in vivo remyelination study using a chemical demyelination
model.
“Battling demyelinating diseases such as
multiple sclerosis requires an understanding of the processes that
cause remyelination to fail. Remyelination of demyelinated
axons is typically a function of oligodendrocyte precursor cells.
These studies will examine the therapeutic role ANAVEX 2-73 may
play in permitting remyelination in the brain,” said Christopher U.
Missling, PhD, President and Chief Executive Officer of Anavex.
About Biogen
Through cutting-edge science and medicine,
Biogen (Nasdaq:BIIB) discovers, develops and delivers worldwide
innovative therapies for people living with serious neurological,
autoimmune and rare diseases. Founded in 1978, Biogen is one of the
world’s oldest independent biotechnology companies and patients
worldwide benefit from its leading multiple sclerosis and
innovative hemophilia therapies. For more information, please visit
www.biogen.com. Follow us on Twitter.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX 2-73, is currently in a Phase 2a clinical trial for
Alzheimer’s disease. ANAVEX 2-73 is an orally available drug
candidate that targets sigma-1 and muscarinic receptors and
successfully completed Phase 1 with a clean safety profile.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer’s disease. It has also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy and others. The
Michael J. Fox Foundation for Parkinson’s Research has awarded
Anavex a research grant to develop ANAVEX 2-73 for the treatment of
Parkinson’s disease to fully fund a preclinical study, which could
justify moving ANAVEX 2-73 into a Parkinson’s disease clinical
trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease modifications against the major Alzheimer’s hallmarks in
transgenic (3xTg-AD) mice, including cognitive deficits, amyloid
and tau pathologies, and also with beneficial effects on
neuroinflammation and mitochondrial dysfunctions. Further
information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
(203) 258-0159
dennisdobsonjr@dobsonmediagroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024